Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-Label Study Of The Safety And Pharmacokinetics Of Repeated-Dose Micafungin (FK463) In Children (2-5 Years AND 6-11 Years) And Adolescents (12-16 Years) With Esophageal Candidiasis Or Other Invasive Candidiasis

NCT00608335 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.

NCT NCT00608335
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00608335 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-Label Study Of The Safety And Pharmacokinetics Of Repeated-Dose Micafungin (FK463) In Children (2-5 Years AND 6-11 Years) And Adolescents (12-16 Years) With Esophageal Candidiasis Or Other Invasive Candidiasis
Lead sponsor
Astellas Pharma Inc
Phase
Phase 1
Overall status
Completed
Start date
October 14, 2007
Completion date
September 8, 2011
Enrollment
84 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

candidemia, esophageal candidiasis, invasive candidiasis, oropharyngeal candidiasis